Teva Pharmaceutical Industries Ltd financial data

Symbol
TEVA on NYSE, TEVJF on OTC
Location
Teva Pharmaceutical Industries Limited, 124 Dvora Hanevi'a St., Tel Aviv, Israel
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 105 % +13.4%
Quick Ratio 27.6 % -7.84%
Debt-to-equity 512 % -1.01%
Return On Equity 11.1 %
Return On Assets 1.81 %
Operating Margin 10.9 % +279%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.15B shares +1.26%
Common Stock, Value, Issued 58M USD 0%
Weighted Average Number of Shares Outstanding, Basic 1.15B shares +1.24%
Weighted Average Number of Shares Outstanding, Diluted 1.16B shares +2.74%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 16.8B USD +0.02%
Selling and Marketing Expense 2.58B USD +3.28%
General and Administrative Expense 1.22B USD +6.17%
Operating Income (Loss) 1.83B USD +279%
Nonoperating Income (Expense) -932M USD +7.91%
Income Tax Expense (Benefit) 239M USD -65.2%
Net Income (Loss) Attributable to Parent 712M USD
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.2B USD -33.6%
Accounts Receivable, after Allowance for Credit Loss, Current 3.81B USD +10.1%
Inventory, Net 3.32B USD -16.1%
Other Assets, Current 477M USD +7.19%
Assets, Current 12.7B USD +3.43%
Deferred Income Tax Assets, Net 1.63B USD -21.1%
Property, Plant and Equipment, Net 4.82B USD -15%
Operating Lease, Right-of-Use Asset 342M USD -6.04%
Goodwill 15.9B USD -1.11%
Other Assets, Noncurrent 444M USD -3.27%
Assets 39.9B USD -4.56%
Employee-related Liabilities, Current 561M USD -9.37%
Liabilities, Current 11.5B USD -16.7%
Operating Lease, Liability, Noncurrent 283M USD -4.07%
Other Liabilities, Noncurrent 3.66B USD -15.7%
Liabilities 32.6B USD -7.84%
Accumulated Other Comprehensive Income (Loss), Net of Tax -2.48B USD +10.6%
Retained Earnings (Accumulated Deficit) -14.2B USD +4.77%
Stockholders' Equity Attributable to Parent 7.25B USD +19.5%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 7.25B USD +13.6%
Liabilities and Equity 39.9B USD -4.56%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 1.07B USD -42.6%
Net Cash Provided by (Used in) Financing Activities -2.87B USD -69.2%
Net Cash Provided by (Used in) Investing Activities 774M USD -13.1%
Common Stock, Shares Authorized 2.5B shares 0%
Common Stock, Shares, Issued 1.25B shares +1.05%
Common Stock, Par or Stated Value Per Share 0.1 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.12B USD -204%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.2B USD -33.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 1.01B USD
Additional Paid in Capital 28B USD +0.64%
Amortization of Intangible Assets 581M USD -1.19%